Over the years, there have been a number of significant advances in the treatment and management of cancer.   However, cancer has been, and continues to be, one of the most challenging diseases to solve. Despite decades of research dedicated to the search for cures, cancer is currently the world’s biggest killer, responsible for the deaths of around 10 million people globally, young and old, every year. For this reason, there is a need to explore new ideas and new concepts. With 18 million new cases of cancer worldwide reported in 2020, and 10 million deaths, there is a need to explo ..read more

Press Release St. Genis-Pouilly, France, 09 March 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that the European Patent Office (”EPO”) has granted patent EP3870574, which covers key compounds in the Company’s broad portfolio of CTPS1 inhibitor assets. The granting of this patent strengthens the Company’s patent portfolio covering its CTPS1 inhibitor assets, which is currently protected by a range of published and unpublished patent families. By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine s ..read more

Press Release St. Genis-Pouilly, France, 3 November 2022 Concr’s proprietary statistical modelling, which uses cosmology methods, will identify biomarkers to help select patients most likely to respond to Step Pharma compounds targeting cytidine triphosphate synthase 1 (CTPS1). St. Genis-Pouilly, France and London, UK, 07 December 2022 – Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, and Concr, a techbio company with a statistical learning-powered biomarker prediction engine, today announced a partnership to identify biomarkers to improve thera ..read more

Press Release St. Genis-Pouilly, France, 24 October 2022 Potential first-in-class targeted treatment for relapsed/refractory T cell and B cell lymphomas Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, announces today that the first patient has been successfully dosed with STP938, in a Phase 1/2 trial in adult subjects with relapsed/refractory B cell and T cell lymphomas. The dose-escalation part of the open label, non-randomised Phase 1/2 trial comprises multiple cohorts dosed with STP938, administered as an oral monotherapy, ascending in a step ..read more

Philip Beer, Chief Scientific Officer at Step Pharma, who is also the Chair of the Genomics Working Group of the British In Vitro Diagnostics Association (BIVDA), provides his perspectives on the recently published report titled “Leveraging partnerships to realise the UK’s potential in genomics” which focuses on the UK genomics landscape and patient access to genomic testing. Philip details the reasons he got involved in BIVDA’s Genomics Working Group and the difference genomic testing can make in cancer treatment. Genetic testing to identify DNA changes in cancer samples has the potential ..read more

Press Release St. Genis-Pouilly, France, 10 May 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that members of its management team will be participating at a number of conferences in May and June 2023. By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer. 23rd Bio€quity Europe, Dublin, Ireland, 15-16 May & 22-23 May Digital Partnering ..read more

Blog April 2023 There are over a hundred different types of blood cancer with the forms of leukemia, lymphoma and myeloma being the most common. Every 3 minutes someone in the US is diagnosed with a blood cancer. For solid tumours, the most common cancers include breast, lung, colon and prostate. Andrew Parker, CEO of Step Pharma, discusses his motivation to lead the Company to focus on a novel target, CTPS1, which is considered to be an Achilles Heel of cancer, in the search for highly selective, safe and effective treatments for both blood cancers and solid tumours.   What was y ..read more

Press Release St. Genis-Pouilly, France, 04 April 2023 Preclinical data published in HemaSphere demonstrate potential of inhibiting CTPS1 as a novel treatment approach for cancer Data further support rationale for developing STP938, currently in clinical trials for the treatment of T cell and B cell lymphoma Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces the publication of compelling preclinical data detailing the therapeutic potential of inhibiting CTPS1 in haematological malignancies. The data, published in HemaSphere (the o ..read more

Press Release St. Genis-Pouilly, France, 04 January 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces the appointment of Dr Philip Beer as Chief Scientific Officer. Philip is a board-certified haematologist with over 16 years of frontline healthcare experience as well as biopharmaceutical industry experience, particularly in translational medicine, drug development, and biomarker discovery. He joined Step Pharma in June 2021 as Vice President, Head of Research & Translation Medicine and has led the Company’s research str ..read more

Press Release St. Genis-Pouilly, France, 12 December 2022 STP938 shows strong anti-tumour effect in preclinical models of mantle cell lymphoma and multiple myeloma STP938 shows synergistic anti-tumour activity in preclinical models when combined with selective inhibitors of other pathways St. Genis-Pouilly, France and London, UK, 12 December 2022 – Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938, were presen ..read more